Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - aciclovir, quantity: 25 mg/ml - injection, solution - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - aciclovir intravenous infusion is indicated for the purpose of:,1. promoting resolution of acute clinical manifestations of mucocutaneous herpes simplex virus infections in immunocompromised patients.,2. treatment of severe first episode primary or non-primary genital herpes in immune competent patients.,3. treatment of acute manifestations of varicella zoster virus infection in immunocompromised patients.,4. treatment of shingles (varicella zoster virus infection) in immune competent patients who show very severe acute local or systemic manifestations of the disease. benefits can be expected in patients with rash duration shorter than 72 hours. the use of the intravenous infusion may be warranted in only a small subgroup of immune competent patients with shingles.,5. treatment of herpes simplex encephalitis.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - aciclovir, quantity: 25 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; water for injections; sodium hydroxide - aciclovir intravenous infusion is indicated for the purpose of:,1. promoting resolution of acute clinical manifestations of mucocutaneous herpes simplex virus infections in immunocompromised patients.,2. treatment of severe first episode primary or non-primary genital herpes in immune competent patients.,3. treatment of acute manifestations of varicella zoster virus infection in immunocompromised patients.,4. treatment of shingles (varicella zoster virus infection) in immune competent patients who show very severe acute local or systemic manifestations of the disease. benefits can be expected in patients with rash duration shorter than 72 hours. the use of the intravenous infusion may be warranted in only a small subgroup of immune competent patients with shingles.,5. treatment of herpes simplex encephalitis.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - aciclovir, quantity: 25 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - aciclovir intravenous infusion is indicated for the purpose of:,1. promoting resolution of acute clinical manifestations of mucocutaneous herpes simplex virus infections in immunocompromised patients.,2. treatment of severe first episode primary or non-primary genital herpes in immune competent patients.,3. treatment of acute manifestations of varicella zoster virus infection in immunocompromised patients.,4. treatment of shingles (varicella zoster virus infection) in immune competent patients who show very severe acute local or systemic manifestations of the disease. benefits can be expected in patients with rash duration shorter than 72 hours. the use of the intravenous infusion may be warranted in only a small subgroup of immune competent patients with shingles.,5. treatment of herpes simplex encephalitis.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - aciclovir sodium dihydrate, quantity: 314.4 mg (equivalent: aciclovir, qty 250 mg) - injection, powder for - excipient ingredients: - aciclovir mylan (aciclovir sodium) is indicated for:,- promoting resolution of acute clinical manifestations of mucocutaneous herpes simplex virus infections in immunocompromised patients,- treatment of severe first episode primary or non-primary genital herpes in immune competent patients,- treatment of acute manifestations of varicella zoster virus infection in immunocompromised patients,- treatment of herpes zoster (shingles) in immune competent patients who show very severe acute local or systemic manifestations of the disease. (benefits can be expected in patients with rash duration shorter than 72 hours. the use of the intravenous infusion may be warranted in only a small subgroup of immune competent patients with shingles).,- treatment of herpes simplex encephalitis.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - aciclovir sodium dihydrate, quantity: 628.8 mg (equivalent: aciclovir, qty 500 mg) - injection, powder for - excipient ingredients: - aciclovir mylan (aciclovir sodium) is indicated for:,- promoting resolution of acute clinical manifestations of mucocutaneous herpes simplex virus infections in immunocompromised patients,- treatment of severe first episode primary or non-primary genital herpes in immune competent patients,- treatment of acute manifestations of varicella zoster virus infection in immunocompromised patients,- treatment of herpes zoster (shingles) in immune competent patients who show very severe acute local or systemic manifestations of the disease. (benefits can be expected in patients with rash duration shorter than 72 hours. the use of the intravenous infusion may be warranted in only a small subgroup of immune competent patients with shingles).,- treatment of herpes simplex encephalitis.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - valaciclovir hydrochloride, quantity: 1112 mg - tablet, film coated - excipient ingredients: magnesium stearate; crospovidone; microcrystalline cellulose; povidone; titanium dioxide; hypromellose; polysorbate 80; macrogol 400; indigo carmine aluminium lake - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash.,for the treatment of ophthalmic zoster.,for the treatment of recurrent herpes labialis (cold sores),for the treatment of clinical episodes of genital herpes simplex infections.,for the prevention of recurrent genital herpes.,reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with valaciclovir, it is recommended that patients use safer sex practices. ,prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - valaciclovir hydrochloride, quantity: 556 mg - tablet, film coated - excipient ingredients: povidone; magnesium stearate; crospovidone; microcrystalline cellulose; titanium dioxide; hypromellose; polysorbate 80; macrogol 400; indigo carmine aluminium lake - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash.,for the treatment of ophthalmic zoster.,for the treatment of recurrent herpes labialis (cold sores),for the treatment of clinical episodes of genital herpes simplex infections.,for the prevention of recurrent genital herpes.,reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with valaciclovir, it is recommended that patients use safer sex practices. ,prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - valaciclovir hydrochloride, quantity: 556 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; magnesium stearate; povidone; titanium dioxide; hypromellose; polysorbate 80; macrogol 400; indigo carmine aluminium lake - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash.,for the treatment of ophthalmic zoster.,for the treatment of recurrent herpes labialis (cold sores),for the treatment of clinical episodes of genital herpes simplex infections.,for the prevention of recurrent genital herpes.,reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with valaciclovir, it is recommended that patients use safer sex practices. ,prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - valaciclovir hydrochloride, quantity: 1112 mg - tablet, film coated - excipient ingredients: magnesium stearate; povidone; crospovidone; microcrystalline cellulose; titanium dioxide; hypromellose; polysorbate 80; macrogol 400; indigo carmine aluminium lake - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash.,for the treatment of ophthalmic zoster.,for the treatment of recurrent herpes labialis (cold sores),for the treatment of clinical episodes of genital herpes simplex infections.,for the prevention of recurrent genital herpes.,reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with valaciclovir, it is recommended that patients use safer sex practices. ,prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - aciclovir, quantity: 800 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate; pregelatinised maize starch; magnesium stearate; colloidal anhydrous silica - aciclovir tablets are indicated for use in adult patients for: (1) the treatment of first episode (primary or non-primary) genital herpes and the management of recurrent episodes of genital herpes in certain patients. (2) the treatment of acute attacks of herpes zoster (shingles) when the duration of rash is less than 72 hours. (3) the management of patients with advaned symptomatic hiv disease cd4 + counts < 150 x 10(6)/l). in accordance with details specified in the "indications" and the "dosage and administration" sections of the approved product information provided as attachment 1.